CNTNAP2–203 interaction with EGFR modulates E2F1 activity and promotes tumorigenesis in oral squamous cell carcinoma
Cellular Signalling · 2025
DOI: 10.1016/j.cellsig.2025.112059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular Signalling, 2025. Verfasst von Lin Zhu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hengyang Medical School, University of South China, Hengyang, Hunan, China; Institute for Future Sciences, University of South China, Changsha, Hunan…. Hauptthemen laut MEDLINE: E2F1 Transcription Factor, Mouth Neoplasms, Membrane Proteins, Carcinogenesis. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Program of Hunan Province, Scientific Research Foundation of Hunan Provincial Education Department.
Abstract (Originalsprache)
CNTNAP2 has two isoforms with confirmed expression: CNTNAP2-201 and CNTNAP2-203. While extensive research has focused on CNTNAP2-201 due to its association with various neurodevelopmental disorders, the role of CNTNAP2-203 in disease pathology remains largely unexplored. Oral squamous cell carcinoma (OSCC) is a major malignancy with high mortality, partially due to limited understanding of its molecular mechanisms. This study demonstrates that CNTNAP2-203 is predominantly expressed and significantly upregulated in OSCC tissues, and elevated CNTNAP2-203 is associated with poorer clinical outcomes. Functionally, CNTNAP2-203 promotes OSCC cell proliferation in vitro and tumor growth in vivo by positively modulating the activity of E2F transcription factor 1 (E2F1), a transcription factor that regulates G1/S cell cycle progression. Mechanistically, CNTNAP2-203 interacts with the epidermal growth factor receptor (EGFR), enhancing EGFR signaling and promoting OSCC tumorigenesis via the EGFR-E2F1 axis. Notably, OSCC cells with elevated CNTNAP2-203 exhibit increased sensitivity to Gefitinib (an EGFR tyrosine kinase inhibitor), either alone or in combination with Cisplatin, suggesting that patients with elevated CNTNAP2-203 may benefit from these treatments. In summary, this study not only elucidates the pathogenic role of CNTNAP2-203 in OSCC but also identifies it as a promising biomarker for guiding therapeutic strategies in OSCC management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hengyang Medical School, University of South China, Hengyang, Hunan, China; Institute for Future Sciences, University of South China, Changsha, Hunan, China; MOE Key Lab of Rare Pediatric Diseases, School of Life Scienc…
- The Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha, Hunan, China.
- Department of Pathology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China.
- Department of Oral and Maxillofacial Surgery, Center of Stomatology, Xiangya Hospital of Central South University, Changsha, Hunan, China.
Förderung
- Science and Technology Program of Hunan Province
- Scientific Research Foundation of Hunan Provincial Education Department
Zitieren
APA
Zhu, L., Ma, S., Jiang, B., Gu, Y., Ye, Y., Xiong, H., Su, T., & Wang, D. (2025). CNTNAP2–203 interaction with EGFR modulates E2F1 activity and promotes tumorigenesis in oral squamous cell carcinoma. Cellular Signalling. https://doi.org/10.1016/j.cellsig.2025.112059
Vancouver
Zhu L, Ma S, Jiang B, Gu Y, Ye Y, Xiong H, et al. CNTNAP2–203 interaction with EGFR modulates E2F1 activity and promotes tumorigenesis in oral squamous cell carcinoma. Cellular Signalling. 2025. doi:10.1016/j.cellsig.2025.112059
BibTeX
@article{Zhu2025,
author = {Zhu, Lin and Ma, Suzhen and Jiang, Binyuan and Gu, Yunyan and Ye, Yu and Xiong, Haofeng and Su, Tong and Wang, Danling},
title = {CNTNAP2–203 interaction with EGFR modulates E2F1 activity and promotes tumorigenesis in oral squamous cell carcinoma},
journal = {Cellular Signalling},
year = {2025},
doi = {10.1016/j.cellsig.2025.112059}
}
EUVIMED